文献速递心境障碍

D-环丝氨酸辅助间歇性θ爆发刺激治疗重性抑郁障碍的疗效:一项随机临床试验

Efficacy of Adjunctive D-Cycloserine to Intermittent Theta-Burst Stimulation for Major Depressive Disorder: A Randomized Clinical Trial.
PubMed 文献 · JAMA Psychiatry · 2022-01-01

这项单中心、4周、双盲、安慰剂对照随机临床试验纳入50例重性抑郁障碍(MDD)患者,比较iTBS联合D-环丝氨酸(100 mg,前2周)与iTBS联合安慰剂的疗效。结果显示,D-环丝氨酸组的MADRS评分改善显著优于安慰剂组,临床应答率和临床缓解率更高,且未发生严重不良事件。

要点

  • D-环丝氨酸辅助iTBS组的MADRS评分改善显著优于安慰剂组(Hedges g=0.99)。
  • D-环丝氨酸组的临床应答率为73.9%,高于安慰剂组的29.3%。
  • D-环丝氨酸组的临床缓解率为39.1%,高于安慰剂组的4.2%,且未发生严重不良事件。

核心结论

  • 辅助D-环丝氨酸可能是增强iTBS治疗MDD疗效的有前景策略,尚需进一步研究。

主要发现

  • iTBS联合D-环丝氨酸组MADRS评分改善优于安慰剂组(均差-6.15;95%CI,-2.43至-9.88;Hedges g=0.99;95%CI,0.34-1.62)。
  • D-环丝氨酸组临床应答率为73.9%,安慰剂组为29.3%;临床缓解率分别为39.1%与4.2%。
  • D-环丝氨酸组CGI严重度评分更低、CGI改善评分更高,未发生严重不良事件。

关键数值与推荐

  • 纳入标准包括年龄18至65岁、原发性MDD诊断、17项汉密尔顿抑郁量表评分≥18、Young躁狂评定量表评分≤8及血检正常。
  • 干预为iTBS联合安慰剂或iTBS联合D-环丝氨酸100 mg,前2周联合用药,第3、4周仅iTBS。

临床怎么用

  • 对于接受iTBS治疗的MDD患者,可考虑联合低剂量D-环丝氨酸以增强疗效,但需在进一步研究证实后推广。

局限性

  • 单中心、样本量50例,研究结果需更大样本进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The antidepressant effects of transcranial magnetic stimulation protocols for major depressive disorder (MDD) are thought to depend on synaptic plasticity. The theta-burst stimulation (TBS) protocol synaptic plasticity is known to be N-methyl-D-aspartate (NMDA)-receptor dependent, yet it is unknown whether enhancing NMDA-receptor signaling improves treatment outcomes in MDD. OBJECTIVE: To test whether low doses of the NMDA-receptor partial-agonist, D-cycloserine, would enhance intermittent TBS (iTBS) treatment outcomes in MDD. DESIGN, SETTING, AND PARTICIPANTS: This was a single-site 4-week, double-blind, placebo-controlled, randomized clinical trial conducted from November 6, 2019, to December 24, 2020, including 50 participants with MDD. Participants were recruited via advertisements and referral. Inclusion criteria were as follows: age 18 to 65 years with a primary diagnosis of MDD, a major depressive episode with score of 18 or more on the 17-item Hamilton Depression Rating Scale, a Young Mania Rating Scale score of 8 or less, and normal blood work (including complete blood cell count, electrolytes, liver function tests, and creatinine level). INTERVENTIONS: Participants were randomly assigned 1:1 to either iTBS plus placebo or iTBS plus D-cycloserine (100 mg) for the first 2 weeks followed by iTBS without an adjunct for weeks 3 and 4. MAIN OUTCOMES AND MEASURES: The primary outcome was change in depressive symptoms as measured by the Montgomery-Åsberg Depression Rating Scale (MADRS) at the conclusion of treatment. Secondary outcomes included clinical response, clinical remission, and Clinical Global Impression (CGI) scores. RESULTS: A total of 50 participants (mean [SD] age, 40.8 [13.4] years; 31 female [62%]) were randomly assigned to treatment groups: iTBS plus placebo (mean [SD] baseline score, 30.3 [4.2]) and iTBS plus D-cycloserine (mean [SD] baseline score, 30.4 [4.5]). The iTBS plus D-cycloserine group had greater improvements in MADRS scores compared with the iTBS plus placebo group (mean difference, -6.15; 95% CI, -2.43 to -9.88; Hedges g = 0.99; 95% CI, 0.34-1.62). Rates of clinical response were higher in the iTBS plus D-cycloserine group than in the iTBS plus placebo group (73.9% vs 29.3%), as were rates of clinical remission (39.1% vs 4.2%). This was reflected in lower CGI-severity ratings and greater CGI-improvement ratings. No serious adverse events occurred. CONCLUSIONS AND RELEVANCE: Findings from this clinical trial indicate that adjunctive D-cycloserine may be a promising strategy for enhancing transcranial magnetic stimulation treatment outcomes in MDD using iTBS requiring further investigation. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03937596.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. Cole J, Sohn MN, Harris AD, et al. Efficacy of Adjunctive D-Cycloserine to Intermittent Theta-Burst Stimulation for Major Depressive Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2022. PMID: 36223114. doi:10.1001/jamapsychiatry.2022.3255

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。